levodopa/carbidopa high dose (ND0612H) / Mitsubishi Tanabe  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
levodopa/carbidopa high dose (ND0612H) / Mitsubishi Tanabe
NCT01883505: A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612

Checkmark In Parkinson's disease
Nov 2015 - Nov 2015: In Parkinson's disease
Checkmark Preliminary results to date
Jan 2015 - Jan 2015: Preliminary results to date
Completed
2
30
RoW
Levodopa and carbidopa, Levodopa and carbidopa or saline, Placebo, Saline
NeuroDerm Ltd.
Parkinson's Disease
04/15
04/15
NCT02577523 / 2015-005078-39: A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

Checkmark Efficacy, PK, safety and tolerability data
Apr 2018 - Apr 2018: Efficacy, PK, safety and tolerability data
Checkmark
Jun 2017 - Jun 2017: 
Checkmark
More
Completed
2
38
Europe, US, RoW
ND0612 (Levodopa/Carbidopa solution), Regimen 1 - 24-hr infusion, ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD, Regimen 2 - 14-hr infusion
NeuroDerm Ltd.
Parkinson's Disease
12/16
01/17
BeyoND, NCT02726386 / 2015-005814-31: A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

Active, not recruiting
2
214
Europe, US, RoW
ND0612, ND0612H
NeuroDerm Ltd.
Parkinson's Disease
09/19
02/27

Download Options